Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 4:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 3,272 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Progenitor Cells Clear all
Completed Not applicable Interventional

Lp-PLA2 and Coronary Atherosclerosis in Humans

NCT01557088
View directory record Official record
Conditions
Coronary Atherosclerosis, Endothelial Dysfunction
Interventions
Blood sampling from the Coronary Sinus and Aorta, Intravascular Ultrasound of the coronary artery.
Other · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 23, 2015 · Synced Oct 17, 2026, 4:27 AM EDT
Completed Phase 1 Interventional

Targeted, Dose-Escalation Busulfan-Etoposide as Prep Regimen

NCT01048827
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Busulfan
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 69 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 11, 2017 · Synced Oct 17, 2026, 4:27 AM EDT
Completed Phase 1 Interventional

Stem Cell Heart Injections During Laser Revascularization Surgery for Treatment of Chronic Ischemic Heart Disease

NCT03043742
View directory record Official record
Conditions
Chronic Ischemic Heart Disease
Interventions
Bone Marrow Derived Autologous CD133+ Selected Cell Product
Drug
Lead sponsor
Michael Sekela
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 11, 2020 · Synced Oct 17, 2026, 4:27 AM EDT
Completed Phase 2 Interventional

Donor Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Relapsed or Refractory Metastatic Kidney Cancer

NCT00262886
View directory record Official record
Conditions
Kidney Cancer
Interventions
anti-thymocyte globulin, graft-versus-tumor induction therapy, therapeutic allogeneic lymphocytes, cyclophosphamide, fludarabine phosphate, mycophenolate mofetil, tacrolimus, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 70 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 6, 2013 · Synced Oct 17, 2026, 4:27 AM EDT
Recruiting Phase 2 Interventional

Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)

NCT03970096
View directory record Official record
Conditions
Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasm
Interventions
Total-Body Irradiation, Thiotepa, Fludarabine, Tacrolimus, Allogeneic CD34+-enriched and CD45RA-depleted PBSCs, Methotrexate, Cyclophosphamide, Peripheral Blood Stem Cell, Cyclosporine, Sirolimus, Busulfan, Bone Marrow Aspiration and Biopsy, Echocardiography, Multigated Acquisition Scan, Biospecimen Collection
Radiation · Drug · Biological + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
1 Year to 60 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
3
States / cities
Tampa, Florida • Pittsburgh, Pennsylvania • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 17, 2026, 4:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Impact of Mesenchymal Stem Cells in Knee Osteoarthritis

NCT03477942
View directory record Official record
Conditions
Musculoskeletal Pain, Knee Osteoarthritis, Cartilage Injury, Cartilage Degeneration
Interventions
Autologous Mesenchymal Stem Cells
Biological
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 17, 2026, 4:27 AM EDT
Completed Phase 1 Interventional

Muscle Progenitor Cell Therapy for Urinary Incontinence

NCT01953315
View directory record Official record
Conditions
Urinary Incontinence
Interventions
Autologous Muscle Progenitor Cells
Biological
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
2
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 1, 2024 · Synced Oct 17, 2026, 4:27 AM EDT
Terminated Phase 1 Interventional Results available

Lenalidomide After Allo-Hematopoietic Cell Transplant (HCT) in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS) Subjects With Minimal Residual Disease

NCT02370888
View directory record Official record
Conditions
Leukemia, Myeloid, Myelodysplastic Syndromes
Interventions
Lenalidomide
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Oct 17, 2026, 4:27 AM EDT
Not listed Phase 2Phase 3 Interventional

Bone Marrow Concentrate (BMC) Injection in Intervertebral Discs

NCT04559295
View directory record Official record
Conditions
Low Back Pain, Disc Disease, Disc Degeneration, Arthropathy Vertebrae, Sacral Disorder, Radiculopathy, Spinal Stenosis
Interventions
Bone Marrow Concentrate
Biological
Lead sponsor
Stem Cures
Other
Eligibility
18 Years to 60 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 22, 2020 · Synced Oct 17, 2026, 4:27 AM EDT
Completed No phase listed Observational

Unrelated Stem Cell Transplantation for Adults With Hematopoietic Disorders

NCT00511537
View directory record Official record
Conditions
CML, ALL, AML, Myelodysplasia, Lymphoma, Myeloproliferative Disorders
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
16 Years to 54 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 2, 2013 · Synced Oct 17, 2026, 4:27 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin Lymphoma

NCT03057795
View directory record Official record
Conditions
Classic Hodgkin Lymphoma, Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
Interventions
Brentuximab Vedotin, Laboratory Biomarker Analysis, Nivolumab
Drug · Other · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
6
States / cities
Duarte, California • Rochester, Minnesota • Hackensack, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 17, 2026, 4:27 AM EDT
Terminated Phase 2 Interventional

Xylitol BSI Multisite - Reduction of Bloodstream Infections From Oral Organisms in Pediatric Stem Cell Transplant

NCT05579639
View directory record Official record
Conditions
Allogeneic Stem Cell Transplantation
Interventions
Xylitol, Placebo
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
4 Months to 25 Years
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Aurora, Colorado • Boston, Massachusetts • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 17, 2026, 4:27 AM EDT
Completed Phase 1 Interventional

Reduced Intensity Stem Cell Transplantation for Chronic Lymphocytic Leukemia Followed by Vaccination

NCT00442130
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
GM-K562 vaccine, stem cell transplantation
Biological · Procedure
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 17, 2020 · Synced Oct 17, 2026, 4:27 AM EDT
Suspended Phase 1 Interventional

Transfer of Bone Marrow Derived Stem Cells for the Treatment of Spinal Cord Injury

NCT01162915
View directory record Official record
Conditions
Spinal Cord Injury
Interventions
Autologous bone marrow-derived mesenchymal stem cells.
Biological
Lead sponsor
TCA Cellular Therapy
Industry
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Covington, Louisiana
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Oct 17, 2026, 4:27 AM EDT
Withdrawn Phase 1 Interventional

Safety and Efficacy Study of HuCNS-SC in Subjects With Neuronal Ceroid Lipofuscinosis

NCT01238315
View directory record Official record
Conditions
Neuronal Ceroid Lipofuscinosis
Interventions
HuCNS-SC
Biological
Lead sponsor
StemCells, Inc.
Industry
Eligibility
6 Months to 6 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 15, 2015 · Synced Oct 17, 2026, 4:27 AM EDT
Active, not recruiting Not applicable Interventional

Standardization of CD3+ T Cell Dose for Patients Receiving Allogeneic Peripheral Blood Stem Cell Transplantation From Matched Related Donors

NCT00959140
View directory record Official record
Conditions
Hematopoietic Stem Cell Transplantation
Interventions
CD3+ T cell depletion
Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 17, 2026, 4:27 AM EDT
Completed Phase 1 Interventional

Escalation of Plerixafor for Mobilization of CD34+ Hematopoietic Progenitor Cells and Evaluation of Globin Gene Transfer in Patients With Sickle Cell Disease

NCT02193191
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Plerixafor
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 17, 2026, 4:27 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of Vadastuximab Talirine Given Prior to or After Allogeneic Hematopoietic Stem Cell Transplant in AML Patients

NCT02614560
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Fludarabine, Melphalan, vadastuximab talirine
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
11
States / cities
Duarte, California • Denver, Colorado • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2019 · Synced Oct 17, 2026, 4:27 AM EDT
Withdrawn Not applicable Interventional

Study to Assess the Safety and Effects of Autologous Adipose-Derived SVF Cells in Patients With Parkinson's Disease

NCT01453803
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Harvesting and Implantation of Adipose-Derived Stem Cells
Procedure
Lead sponsor
Ageless Regenerative Institute
Industry
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Aventura, Florida
Source: ClinicalTrials.gov public record
Updated Nov 24, 2017 · Synced Oct 17, 2026, 4:27 AM EDT
Completed No phase listed Observational Results available

Caregiver Burden and Distress in Hematopoeitic Stem Cell Transplant

NCT01084694
View directory record Official record
Conditions
Depression, Anxiety, Fatigue, Distress
Interventions
Not listed
Lead sponsor
Northside Hospital, Inc.
Other
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 7, 2020 · Synced Oct 17, 2026, 4:27 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Adult Human Mesenchymal Stem Cells to Treat Steroid Refractory Acute Graft Versus Host Disease (GVHD)

NCT00366145
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
Prochymal®, Placebo, Standard of Care for GVHD
Biological · Drug
Lead sponsor
Mesoblast, Inc.
Industry
Eligibility
6 Months to 70 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
47
States / cities
Birmingham, Alabama • Tucson, Arizona • Duarte, California + 35 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2022 · Synced Oct 17, 2026, 4:27 AM EDT
Completed Phase 2 Interventional Results available

The Effect of Rituximab on Mobilization With AMD3100 (Plerixafor) Plus G-CSF in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) or Hodgkin Disease (HD)

NCT00444912
View directory record Official record
Conditions
Non-Hodgkin Lymphoma, Hodgkin Disease
Interventions
G-CSF plus plerixafor, rituximab
Drug · Biological
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 13, 2014 · Synced Oct 17, 2026, 4:27 AM EDT
Not listed Phase 1 Interventional

Autologous CD34+ Stem Cell Injection for Severe Intermittent Claudication (Leg Pain)

NCT00311805
View directory record Official record
Conditions
Peripheral Artery Disease, Severe Intermittent Claudication
Interventions
Autologous Stem Cells (CD34+)
Biological
Lead sponsor
Losordo, Douglas, M.D.
Individual
Eligibility
21 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
2
States / cities
Birmingham, Alabama • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 31, 2015 · Synced Oct 17, 2026, 4:27 AM EDT
Enrolling by invitation Phase 3 Interventional

A Long-term Follow-up Study in Participants Who Received CTX001

NCT04208529
View directory record Official record
Conditions
Beta-Thalassemia, Thalassemia, Sickle Cell Disease, Hematologic Diseases, Hemoglobinopathies, Genetic Diseases, Inborn, Sickle Cell Anemia
Interventions
CTX001
Biological
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
2 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2039
U.S. locations
9
States / cities
Palo Alto, California • Chicago, Illinois • New York, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 17, 2026, 4:27 AM EDT